Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Leningrado Association in Hypertension
NCT03814109Phase 3Withdrawn
- Sponsor
- EMS
- Start
- Apr 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of indapamide + levamlodipine in hypertension (HTN) (3 arms), sponsored by EMS. Primary endpoint: Change in systolic blood pressure levels at 56 days. Planned start Apr 2022; status: withdrawn.
02
Drugs
indapamide + levamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03814109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03814109.